3,853 research outputs found
Design of a single ultra-low-loss magnetic ballast for a wide range of T5 high-efficiency fluorescent lamps
A patent-pending single design of an ultralow-loss (ULL) magnetic ballast for T5 high-efficient (T5-HE) fluorescent lamps rated from 14 to 35 W is presented. Based on the use of a nonlinear physical low-pressure discharge lamp model, it is discovered that the same set of ballast parameters can be chosen for operating T5-HE 14-, 21-, 28-, and 35-W lamps at their respective rated power at a mains voltage in the range of 220-240 V. With energy efficiency higher than and lifetime much longer than their electronic counterparts and being recyclable, the ULL ballasts offer a more environmentally friendly solution to T5-HE lamps than electronic ballasts. This single-ballast design offers great convenience to both ballast manufacturers and users, because only one product design can cover a range of the most popular T5-HE lamps. Both theoretical analysis and experimental results are included to confirm the validity of the proposal. © 2011 IEEE.published_or_final_versio
A "Class-A2" ultra-low-loss magnetic ballast for T5 fluorescent lamps - A new trend for sustainable lighting technology
The high-voltage and low-current features of T5 lamps imply that the copper and core losses of the magnetic ballast can be greatly reduced. This paper shows that magnetic ballasts for high-voltage T5 lamps are not only feasible but their luminous and ballast-loss performance can be better than those of the electronic ballasts. Contrary to common belief, high frequency operation of T5 28 W lamps increases the luminous efficacy by an average of 3.6% only (less than 5%). Practical implementation of an ultra-low-loss magnetic ballast system for T5 28 W lamps is presented. Its total system power is less than the 32 W upper limit specified for Class A2 of energy-efficient electronic ballast for T5 28 W lamps. High-luminous efficacy of 75.63-77.66 lm/W can be achieved. This important breakthrough has the potential of reversing the existing trend of using electronic ballasts as the energy-saving technology in lighting industry. With a better luminous efficacy, lower product and maintenance costs, much longer lifetime, and the use of recyclable metallic materials over its electronic counterparts, this patent-pending proposal provides a truly sustainable lighting solution to the lighting industry. © 2006 IEEE.published_or_final_versio
A "Class-A2" ultra-low-loss magnetic ballast for T5 fluorescent lamps - A new trend for sustainable lighting technology
The high-voltage and low-current features of T5 lamps imply that the copper and core losses of the magnetic ballast can be greatly reduced. This paper shows that magnetic ballasts for high-voltage T5 lamps are not only feasible but their luminous and ballast-loss performance can be better than those of the electronic ballasts. Contrary to common belief, high frequency operation of T5 28 W lamps increases the luminous efficacy by an average of 3.6% only (less than 5%). Practical implementation of an ultra-low-loss magnetic ballast system for T5 28 W lamps is presented. Its total system power is less than the 32 W upper limit specified for Class A2 of energy-efficient electronic ballast for T5 28 W lamps. High-luminous efficacy of 75.63-77.66 lm/W can be achieved. This important breakthrough has the potential of reversing the existing trend of using electronic ballasts as the energy-saving technology in lighting industry. With a better luminous efficacy, lower product and maintenance costs, much longer lifetime, and the use of recyclable metallic materials over its electronic counterparts, this patent-pending proposal provides a truly sustainable lighting solution to the lighting industry. © 2006 IEEE.published_or_final_versio
Crude incidence in two-phase designs in the presence of competing risks.
BackgroundIn many studies, some information might not be available for the whole cohort, some covariates, or even the outcome, might be ascertained in selected subsamples. These studies are part of a broad category termed two-phase studies. Common examples include the nested case-control and the case-cohort designs. For two-phase studies, appropriate weighted survival estimates have been derived; however, no estimator of cumulative incidence accounting for competing events has been proposed. This is relevant in the presence of multiple types of events, where estimation of event type specific quantities are needed for evaluating outcome.MethodsWe develop a non parametric estimator of the cumulative incidence function of events accounting for possible competing events. It handles a general sampling design by weights derived from the sampling probabilities. The variance is derived from the influence function of the subdistribution hazard.ResultsThe proposed method shows good performance in simulations. It is applied to estimate the crude incidence of relapse in childhood acute lymphoblastic leukemia in groups defined by a genotype not available for everyone in a cohort of nearly 2000 patients, where death due to toxicity acted as a competing event. In a second example the aim was to estimate engagement in care of a cohort of HIV patients in resource limited setting, where for some patients the outcome itself was missing due to lost to follow-up. A sampling based approach was used to identify outcome in a subsample of lost patients and to obtain a valid estimate of connection to care.ConclusionsA valid estimator for cumulative incidence of events accounting for competing risks under a general sampling design from an infinite target population is derived
Semiparametric methods for genome-wide linkage analysis of human gene expression data
With the availability of high-throughput microarray technologies, investigators can simultaneously measure the expression levels of many thousands of genes in a short period. Although there are rich statistical methods for analyzing microarray data in the literature, limited work has been done in mapping expression quantitative trait loci (eQTL) that influence the variation in levels of gene expression. Most existing eQTL mapping methods assume that the expression phenotypes follow a normal distribution and violation of the normality assumption may lead to inflated type I error and reduced power. QTL analysis of expression data involves the mapping of many expression phenotypes at thousands or hundreds of thousands of marker loci across the whole genome. An appropriate procedure to adjust for multiple testing is essential for guarding against an abundance of false positive results. In this study, we applied a semiparametric quantitative trait loci (SQTL) mapping method to human gene expression data. The SQTL mapping method is rank-based and therefore robust to non-normality and outliers. Furthermore, we apply an efficient Monte Carlo procedure to account for multiple testing and assess the genome-wide significance level. Particularly, we apply the SQTL mapping method and the Monte-Carlo approach to the gene expression data provided by Genetic Analysis Workshop 15
RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus
Epstein-Barr virus (EBV) immortalizes resting B-cells and is a key etiologic agent in the development of numerous cancers. The essential EBV-encoded protein EBNA 2 activates the viral C promoter (Cp) producing a message of ~120 kb that is differentially spliced to encode all EBNAs required for immortalization. We have previously shown that EBNA 2-activated transcription is dependent on the activity of the RNA polymerase II (pol II) C-terminal domain (CTD) kinase pTEFb (CDK9/cyclin T1). We now demonstrate that Cp, in contrast to two shorter EBNA 2-activated viral genes (LMP 1 and 2A), displays high levels of promoter-proximally stalled pol II despite being constitutively active. Consistent with pol II stalling, we detect considerable pausing complex (NELF/DSIF) association with Cp. Significantly, we observe substantial Cp-specific pTEFb recruitment that stimulates high-level pol II CTD serine 2 phosphorylation at distal regions (up to +75 kb), promoting elongation. We reveal that Cp-specific pol II accumulation is directed by DNA sequences unfavourable for nucleosome assembly that increase TBP access and pol II recruitment. Stalled pol II then maintains Cp nucleosome depletion. Our data indicate that pTEFb is recruited to Cp by the bromodomain protein Brd4, with polymerase stalling facilitating stable association of pTEFb. The Brd4 inhibitor JQ1 and the pTEFb inhibitors DRB and Flavopiridol significantly reduce Cp, but not LMP1 transcript production indicating that Brd4 and pTEFb are required for Cp transcription. Taken together our data indicate that pol II stalling at Cp promotes transcription of essential immortalizing genes during EBV infection by (i) preventing promoter-proximal nucleosome assembly and ii) necessitating the recruitment of pTEFb thereby maintaining serine 2 CTD phosphorylation at distal regions
Magnetic Fluffy Dark Matter
We explore extensions of inelastic Dark Matter and Magnetic inelastic Dark
Matter where the WIMP can scatter to a tower of heavier states. We assume a
WIMP mass GeV and a constant splitting between
successive states keV. For the
spin-independent scattering scenario we find that the direct experiments CDMS
and XENON strongly constrain most of the DAMA/LIBRA preferred parameter space,
while for WIMPs that interact with nuclei via their magnetic moment a region of
parameter space corresponding to GeV and keV
is allowed by all the present direct detection constraints.Comment: 16 pages, 6 figures, added comments about magnetic moment form factor
to Sec 3.1.2 and results to Sec 3.2.2, final version to be published in JHE
Empirical study of correlated survival times for recurrent events with proportional hazards margins and the effect of correlation and censoring.
Background: In longitudinal studies where subjects experience recurrent incidents over a period of time, such as respiratory infections, fever or diarrhea, statistical methods are required to take into account the within-subject correlation. Methods: For repeated events data with censored failure, the independent increment (AG), marginal (WLW) and conditional (PWP) models are three multiple failure models that generalize Cox"s proportional hazard model. In this paper, we revise the efficiency, accuracy and robustness of all three models under simulated scenarios with varying degrees of within-subject correlation, censoring levels, maximum number of possible recurrences and sample size. We also study the methods performance on a real dataset from a cohort study with bronchial obstruction. Results: We find substantial differences between methods and there is not an optimal method. AG and PWP seem to be preferable to WLW for low correlation levels but the situation reverts for high correlations. Conclusions: All methods are stable in front of censoring, worsen with increasing recurrence levels and share a bias problem which, among other consequences, makes asymptotic normal confidence intervals not fully reliable, although they are well developed theoretically
Analytic philosophy for biomedical research: the imperative of applying yesterday's timeless messages to today's impasses
The mantra that "the best way to predict the future is to invent it" (attributed to the computer scientist Alan Kay) exemplifies some of the expectations from the technical and innovative sides of biomedical research at present. However, for technical advancements to make real impacts both on patient health and genuine scientific understanding, quite a number of lingering challenges facing the entire spectrum from protein biology all the way to randomized controlled trials should start to be overcome. The proposal in this chapter is that philosophy is essential in this process. By reviewing select examples from the history of science and philosophy, disciplines which were indistinguishable until the mid-nineteenth century, I argue that progress toward the many impasses in biomedicine can be achieved by emphasizing theoretical work (in the true sense of the word 'theory') as a vital foundation for experimental biology. Furthermore, a philosophical biology program that could provide a framework for theoretical investigations is outlined
Disparities and risks of sexually transmissible infections among men who have sex with men in China: a meta-analysis and data synthesis.
BACKGROUND: Sexually transmitted infections (STIs), including Hepatitis B and C virus, are emerging public health risks in China, especially among men who have sex with men (MSM). This study aims to assess the magnitude and risks of STIs among Chinese MSM. METHODS: Chinese and English peer-reviewed articles were searched in five electronic databases from January 2000 to February 2013. Pooled prevalence estimates for each STI infection were calculated using meta-analysis. Infection risks of STIs in MSM, HIV-positive MSM and male sex workers (MSW) were obtained. This review followed the PRISMA guidelines and was registered in PROSPERO. RESULTS: Eighty-eight articles (11 in English and 77 in Chinese) investigating 35,203 MSM in 28 provinces were included in this review. The prevalence levels of STIs among MSM were 6.3% (95% CI: 3.5-11.0%) for chlamydia, 1.5% (0.7-2.9%) for genital wart, 1.9% (1.3-2.7%) for gonorrhoea, 8.9% (7.8-10.2%) for hepatitis B (HBV), 1.2% (1.0-1.6%) for hepatitis C (HCV), 66.3% (57.4-74.1%) for human papillomavirus (HPV), 10.6% (6.2-17.6%) for herpes simplex virus (HSV-2) and 4.3% (3.2-5.8%) for Ureaplasma urealyticum. HIV-positive MSM have consistently higher odds of all these infections than the broader MSM population. As a subgroup of MSM, MSW were 2.5 (1.4-4.7), 5.7 (2.7-12.3), and 2.2 (1.4-3.7) times more likely to be infected with chlamydia, gonorrhoea and HCV than the broader MSM population, respectively. CONCLUSION: Prevalence levels of STIs among MSW were significantly higher than the broader MSM population. Co-infection of HIV and STIs were prevalent among Chinese MSM. Integration of HIV and STIs healthcare and surveillance systems is essential in providing effective HIV/STIs preventive measures and treatments. TRIAL REGISTRATION: PROSPERO NO: CRD42013003721
- …
